Ross Barrett
Angel Investor · at Cancer Focus Fund
Shreveport, United States
Ross Barrett is a Series A investor at Cancer Focus Fund in Shreveport focused on Biotechnology and Medical. Ross Barrett is the Co-Founder, President, and Manager of Lagniappe Labs. He attended New York University School of Law.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Ross Barrett invests in
Stages Ross Barrett invests in
Countries Ross Barrett invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (50%)
- Medical 2 (25%)
- Health Care 2 (25%)
- Life Science 2 (25%)
- Therapeutics 2 (25%)
Stage
- Series A 3 (38%)
- Venture - Series Unknown 3 (38%)
- Seed 1 (13%)
- Funding Round 1 (13%)
Country
- Israel 2 (25%)
- United States 2 (25%)
- Germany 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues. | $18M / Series A / Feb 18, 2026 | ||
| Starget Pharma develops a new generation of targeted radiopharmaceutical technologies for the treatment of solid tumors. Starget Pharma has a pipeline of novel targeted radiopharmaceutical molecules that act as a vector for selectively transferring radioisotopes to cancer tumor tissues. | $5.1M / Venture - Series Unknown / Oct 23, 2024 | ||
| March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $28.4M / Series A / Oct 23, 2024 | ||
| Eisbach Bio is a biotechnology company that creates new drugs that target molecular vulnerabilities in cancer genomes. Screening and cellular platforms are yielding first-in-class inhibitors to directly target the key vulnerability found in genetically defined tumors. It is founded in 2019 and is based in Martinsried, Bavaria. | $4.5M / Venture - Series Unknown / Mar 21, 2024 | ||
| March Biosciences is a clinical-stage cell therapy company that focuses on developing CAR-T cell strategies to address hematological cancers. | $4.8M / Seed / Nov 09, 2023 | ||
| ImmunoGenesis develops science-driven immune therapies specifically designed to treat tumors lacking activated T cells or having other immune resistance mechanisms. | $4.5M / Venture - Series Unknown / Jun 27, 2023 | ||
| Nectin Therapeutics is developing novel monoclonal antibodies directed towards members of the Nectin family of receptors and ligands that have major roles in the immune checkpoint mechanisms relevant for cancer immune therapy. These novel antibodies are developed for the treatment of solid and hematological malignancies. | $5.4M / Series A / Mar 07, 2022 | ||
| See all 8 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ross Barrett invest in?
Ross Barrett invests primarily in Biotechnology, Medical and Health Care startups, most often at Series A and Venture - Series Unknown stage. Most of the 8 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ross Barrett?
Public channels for Ross Barrett include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ross Barrett last invest?
The most recent investment recorded for Ross Barrett closed in Feb 2026. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
